Found GLP-1 Program: What the Telehealth Option Includes

Part of the PlexusDx Education Hub, this review sits alongside our library on GLP-1 pharmacology, weight-management protocols, and the inherited factors that shape metabolic response. Explore the full Peptides & GLP-1 collection.

Independent editorial coverage. PlexusDx holds no commercial relationship with Found or its parent company, and nothing here is a paid placement or affiliate arrangement.

Full head-to-head: PlexusDx vs Found →

Search interest in Found's GLP-1 option usually comes down to one practical question: what does the subscription actually put in your hands? This review walks through the medication side of Found — the compounds it can route, the dispensing pathways behind them, and the clinical scaffolding around a prescription — then names the one input the whole model leaves out. As of April 2026.

Where Found sits in the GLP-1 telehealth landscape

Found is one of many subscription telehealth services competing for the GLP-1 patient. In this model, care is delivered virtually: a licensed provider evaluates you, writes a prescription when appropriate, and routes it either to a retail pharmacy for FDA-approved brand products or to a 503A compounding pharmacy for compounded semaglutide or tirzepatide. Ongoing follow-up rounds out the offering. The brand's current structure and pricing live on Found's official website.

The GLP-1 offering: what a prescription actually covers

What a GLP-1 subscription hands you is a clinician-authorized supply of a specific compound plus the service wrapper around it. Whether that compound is an FDA-approved brand product or a compounded 503A preparation depends on eligibility, availability, and the pharmacy pathway a given order uses. The subscription itself does not change the molecule; it changes how you reach it and how your dosing is supported over time.

From intake to first shipment

The workflow is consistent across programs of this type. You complete an intake covering weight, medical history, and current medications. A licensed clinician reviews it and, if you qualify, issues a prescription. That order is fulfilled by a retail or licensed compounding pharmacy, and follow-up visits support titration and side-effect management. What varies between brands is the provider type — physician versus nurse practitioner or physician assistant — and the pharmacy partner.

What you pay for in a GLP-1 subscription

Published pricing for Found appears on its own site and shifts over time. Your monthly total reflects the program fee, the medication itself, the subscription tier, and whether you receive a brand product or a compounded alternative. Across the telehealth GLP-1 market as of April 2026, monthly totals commonly land somewhere between roughly $200 and $700+, with wide spread. Confirm current figures at Found's official website before committing.

The compound does the work, not the brand

Any legitimate GLP-1 program is pharmacologically defined by its compounds, not its logo. GLP-1 receptor agonists — semaglutide, liraglutide, dulaglutide — and the GIP/GLP-1 dual agonist tirzepatide carry the clinical evidence. Landmark programs include STEP (semaglutide for weight management, The New England Journal of Medicine, 2021), SURMOUNT (tirzepatide for weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024). Trial populations and endpoints differ, and individual outcomes vary.

The genetic variable no subscription reads

Here is the layer none of these telehealth workflows examine: the inherited biology that sets the stage before any GLP-1 molecule arrives. Variants in FTO, the fat-mass and obesity-associated gene, together with GLP1R — the receptor every GLP-1 compound binds — and MC4R, a hub for satiety and energy balance, sketch the metabolic baseline a prescription lands on. These are pathway-level markers. They do not predict how you will respond to any particular drug, but they describe the metabolic terrain a prescriber is writing into. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights across that terrain, mapping appetite regulation, satiety, and energy-balance biology so a conversation with your own clinician starts from data rather than guesswork. It is not a pharmacogenomic test and never forecasts a medication's effect.

PlexusDx runs its own Weight Management Protocols, offering semaglutide and tirzepatide as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. The distinction is sequence: the genetic read comes first, then the protocol — a test-before-you-invest approach most GLP-1 subscriptions skip.

Not affiliated: PlexusDx has no affiliation and no commercial relationship with Found or the other programs discussed in this review.

Related reading on PlexusDx: GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone.

Educational content only. PlexusDx is unaffiliated with Found and has no commercial relationship with the programs discussed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols; this review compares approaches within GLP-1 telehealth. The Precision Peptide Genetic Test examines how your genes influence peptide-related pathways and does not predict any medication's effect. Talk with a qualified clinician before starting a peptide protocol.

Weigh the PlexusDx route: review the Weight Management Protocols for semaglutide and tirzepatide with genetic context built in, or order the Precision Peptide Genetic Test to read your GLP-1 pathway before you commit.

Frequently Asked Questions

What GLP-1 medications does Found offer?

Found routes GLP-1 receptor agonists such as semaglutide and the dual agonist tirzepatide, dispensed either as FDA-approved brand products through a retail pharmacy or as compounded 503A preparations, depending on eligibility and availability. The exact options and formulations are listed on the brand's own website, which you should check directly.

Does Found prescribe compounded or brand-name GLP-1s?

It can do either. The dispensing pathway depends on eligibility, availability, and how a given order is fulfilled — a retail pharmacy for FDA-approved brand products or a licensed 503A compounding pharmacy for compounded semaglutide or tirzepatide. The subscription changes access, not the underlying molecule you receive.

Is a Found GLP-1 prescription right for everyone?

No program suits everyone. Eligibility is determined by a licensed clinician after reviewing your intake, history, and current medications, and outcomes vary from person to person. A prescription is a clinical decision made with a provider, not an automatic result of signing up for any GLP-1 subscription.

How does the Precision Peptide Genetic Test fit alongside a GLP-1 program?

It works upstream. The Precision Peptide Genetic Test does not predict how you will respond to any compound or program; it maps pathway-level variants in genes like FTO, MC4R that describe your baseline metabolic biology — context that applies regardless of which service writes the prescription.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education.